Mankind Pharma Licenses Two Insulin Products from Chongqing Chenan Biopharmaceutical
Mankind Pharma has entered an exclusive in-licensing and marketing agreement with China's Chongqing Chenan Biopharmaceutical to commercialize two insulin products in India: Insulin Degludec and a combination of Insulin Degludec and Insulin Aspart. This partnership aims to expand Mankind Pharma's injectable diabetes portfolio and improve access to advanced therapies for Indian patients. The deal aligns with the company's strategy to leverage global pharmaceutical innovations and strengthen its presence in the diabetes-care market through licensing partnerships.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (72/100). Lens Score 38/100.
Outlets measured: freepressjournal, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (68–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 20 Aug, 08:21 am. Other outlets followed.